Mobile website
Archive > Volume 21 Issue 2 > 2014,21(2):119-124. DOI:10.3872/j.issn.1007-385X.2014.02.001 Prev Next
Expert Forum
Clinical trials on oncolytic viruses in cancer therapy: Review and prospects
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Viruses have been used in the treatment of cancers for more than 100 years. As the understanding of various oncolytic viruses deepens, it is more feasible to perform targeted manipulation of viral genes and thus control their behaviors and functions. Since the report of gene-modification of herpes simplex virus type 1 (HSV-1) in 1991, multi-gene recombination of oncolytic viruses (e.g. adenovirus and vaccinia virus) has been attempted. To date, more than 100 clinical trials on the application of wild-type, genetically modified or naturally mutated oncolytic viruses in cancer therapy have been registered worldwide; some of these trials have been completed while others are still ongoing. Overall, the use of oncolytic viruses for most of the common cancers evaluated has been demonstrated to be safe and encouraging clinical outcomes have been obtained. In this review paper, we attempt to outline the past achievements made from, the currently existing problems with, and the future directions and perspectives of clinical trials on oncolytic viruses in cancer therapy.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China （No. 81360346）， the Social Developmental Research Foundation from Bureau of Science and Technology of Guizhou Province （No.SY\[2012\]3094)， and the Joint Social Development Foundation from Bureau of Science and Technology of Guizhou Province and Guiyang Medical College (No.\[2011\]011)
Clc Number:
